PTC Therapeutics CEO Makes Significant Stock Sale!
PTC Therapeutics CEO Matthew B. Klein sold 3,428 shares worth $271,051 on December 3, 2025. The company has seen significant stock activity due to strong Q3 earnings and the launch of Sephience. RBC Capital downgraded the stock, while Goldman Sachs and TD Cowen raised their price targets. Despite challenges, the earnings call was positive. TipRanks’ AI Analyst rates PTCT as Outperform, citing strong technical indicators and favorable valuation.
Tip Ranks·